SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: james who wrote (2918)11/21/1997 12:13:00 AM
From: Pseudo Biologist  Read Replies (2) of 6136
 
Wow, that's a lot of info. Let's take one at a time. First, when people say "preventive" vaccine they usually mean that it is used before any infection. Therapeutic, as you said, would be used to treat an already infected patient.

The so-called naked DNA approach has been tried in people for gene therapy (cf. recent VEGF-2 data from St. Elizabeth's hospital and HGSI) and for vaccination as Merck is doing for influenza. There are many many papers of this in animals; however, I understand it is tricky to get it to work.

As said here before AGPH has a number of interesting targets; for some of those they may be the only (or the first) to have solved the 3D structure. Given their approach this gives them a big advantage.

Viracept is not a peptido-mimetic (while the early PIs are); see an excellent post in this thread exchange2000.com
where the manufacturing issues are discussed. Ask Dr. Oliver about the bio-availability and the apparent discrepancy between Ki and dosage.

Finally, on the CEGE UR approach. Note that they can use, and have used, CD4 itself instead of an antibody; presumably the recoginition site on gp120 for CD4 cannot change too much without rendering the virus unable of infection. I do not recall what they are using in the clinic. In vivo Abs (or CD4 fusion proteins, for example) seldom have enough cell-killing power (via complement or ADCC); that's why people often couple MAbs to radioactive isotopes or to toxins (immunotoxins), and why CEGE and others bother with these complicated T-cell approaches.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News